Not yet recruitingObservationalUpdated Apr 19, 2021
Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy | NCT06631352 | Trialant
CompletedObservationalUpdated Oct 8, 2024
Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy
Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy
ClinicalTrials.gov ID
NCT06631352
Lead Sponsor
Seoul National University HospitalOTHER
Overall Status
Completed
Study Type
Observational
Enrollment
50Actual
Last Update Posted
Oct 8, 2024Actual
Start Date
Jan 1, 2000Actual
Primary Completion Date
Dec 31, 2023Actual
Completion Date
May 31, 2024Actual
Official Title
Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy
Brief Summary
In biliary tract malignancies, achieving a microscopically clear resection margin (R0) is considered the only treatment for a cure.
Hepatopancreatoduodenectomy(HPD) has been considered a surgical option for patients with extensive bile duct or gallbladder cancer to achieve an R0 resection.
The associated high morbidity and mortality rates have prevented HPD from becoming a standard surgical procedure worldwide.
Over the past few decades, the understanding of the bile duct anatomy has significantly improved, and many methods have been developed to assess liver function and future remnant liver volume.
We aimed to evaluate the short- and long-term outcomes of HPD and to assess risk factors associated with survival, early recurrence, and major complications to better evaluate the potential of the procedure as a standard treatment.
Hepatopancreaticobiliary (HPB) Malignancy
Gall Bladder Cancer
Bile Duct Cancer
Pancreatoduodenectomy
Hepatectomy
Hepatopancreatoduodenectomy
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who received hepatopancreatoduodenectomy between January 2000 and December 2023.